SCHEMBL19920575

SCHEMBL19920575

CC(C)(C)OC(=O)NC1(C(N)=O)CC(F)(F)C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
MAPK1 P28482 1/20 0.35
APLNR P35414 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
CA12 O43570 1/20 0.33
CA14 Q9ULX7 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CTSL P07711 1/20 0.32
GHSR Q92847 1/20 0.31
TSHR P16473 1/20 0.31
FSHR P23945 1/20 0.31
NFKB1 P19838 1/20 0.30
NFKB2 Q00653 1/20 0.30
RELA Q04206 1/20 0.30
DPP8 Q6V1X1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20054418 0.85 TSHR (0.37) KMT2AMEN1MAPK1APLNRCA12
SCHEMBL6888403 0.85 KMT2A (0.36) KMT2AMEN1MAPK1APLNRTDP1
SCHEMBL22380393 0.84 MEN1 (0.33) KMT2AMEN1MAPK1APLNRCA1
SCHEMBL22362839 0.83 MEN1 (0.35) KMT2AMEN1MAPK1APLNRTDP1
SCHEMBL2392486 0.82 KMT2A (0.38) KMT2AMEN1MAPK1APLNRTDP1
SCHEMBL19920518 0.82 SLC10A1 (0.35) KMT2AMEN1MAPK1APLNRCA1
SCHEMBL17605642 0.82 MEN1 (0.34) KMT2AMEN1MAPK1APLNRCA1
SCHEMBL5104037 0.81 KMT2A (0.33) KMT2AMEN1MAPK1TDP1MAOA
SCHEMBL4742076 0.79 KMT2A (0.36) KMT2AMEN1MAPK1APLNRTDP1
SCHEMBL2716648 0.79 KMT2A (0.36) KMT2AMEN1MAPK1APLNRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12161625-B2 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. (US) 2024-12-10 US disclosed
EP-3922634-B1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES INC (US) 2023-10-25 EP disclosed
EP-3922634-B1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES INC (US) 2023-10-25 EP disclosed
US-20230270719-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2023-08-31 US disclosed
US-20230270719-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2023-08-31 US disclosed
US-20230097871-A1 UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR TAISHO PHARMACEUTICAL CO., LTD. (JP) 2023-03-30 US disclosed
EP-4008405-A1 UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR Taisho Pharmaceutical Co., Ltd. (JP) 2022-06-08 EP disclosed
EP-3922634-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF Gilead Sciences, Inc. (US) 2021-12-15 EP disclosed
US-20210251957-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2021-08-19 US disclosed
EP-3504212-B1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES INC (US) 2021-05-19 EP disclosed
US-10874640-B2 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. (US) 2020-12-29 US disclosed
US-20200268730-A1 AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES JANSSEN PHARMACEUTICA NV (BE) 2020-08-27 US disclosed
US-20200061024-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2020-02-27 US disclosed
US-10328053-B2 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. (US) 2019-06-25 US disclosed
CN-109790168-A SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF 吉利德科学公司 2019-05-21 CN disclosed
US-20180161307-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2018-06-14 US disclosed
WO-2018039531-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2018-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200061024-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF HMBS, DHFR, HCCS KMT2A 2946/4885MEN1 3929/4885MAPK1 3270/4885
US-12161625-B2 Substituted pyrrolizine compounds and uses thereof HMBS, DHFR, HCCS KMT2A 2946/4885MEN1 3929/4885MAPK1 3270/4885
US-20230097871-A1 UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR LPAR1, LPAR2, LPAR3 KMT2A 2533/4885MEN1 2436/4885MAPK1 133/4885
US-10328053-B2 Substituted pyrrolizine compounds and uses thereof HMBS, DHFR, HCCS KMT2A 2946/4885MEN1 3929/4885MAPK1 3270/4885
US-20230270719-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF HMBS, DHFR, HCCS KMT2A 2946/4885MEN1 3929/4885MAPK1 3270/4885
US-20200268730-A1 AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES HDGF, FABP1, NR1H4 KMT2A 2809/4885MEN1 4681/4885MAPK1 3282/4885
US-10874640-B2 Substituted pyrrolizine compounds and uses thereof HMBS, DHFR, HCCS KMT2A 2946/4885MEN1 3929/4885MAPK1 3270/4885
US-20180161307-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF HMBS, DHFR, HCCS KMT2A 2946/4885MEN1 3929/4885MAPK1 3270/4885
US-20210251957-A1 SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF HMBS, DHFR, HCCS KMT2A 2946/4885MEN1 3929/4885MAPK1 3270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.